Citigroup Maintains Neutral on Clorox, Lowers Price Target to $97
Citigroup analyst Filippo Falorni maintains Clorox (NYSE:CLX) with a Neutral and lowers the price target from $100 to $97.
Stocks · News reference
Wall Street analysts change outlook on top stocks. See upgrade, downgrade, and initiation changes on our analyst ratings page. CLX stock has mixed reviews.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Citigroup analyst Filippo Falorni maintains Clorox (NYSE:CLX) with a Neutral and lowers the price target from $100 to $97.
Wells Fargo analyst Chris Carey maintains Clorox (NYSE:CLX) with a Equal-Weight and lowers the price target from $102 to $90.
Newsweek announced its fourth annual World's Most Trustworthy Companies ranking, recognizing 1,000 companies across 20 countries based on customer, employee, and investor trust. Wyndham Hotels & Resorts, Campbell's, Nintendo, Samsung SDS, Linde, Clorox, and Tesco ranked No. 1 in their respective industries. The ranking evaluated over 65,000 survey participants and 200,000 company evaluations across three trust dimensions.
Investors turn to dividend-yielding stocks during market turbulence. Benzinga provides latest analyst ratings and accurate picks for high-yielding consumer staples stocks.
Tapestry (TPR) projects fiscal 2027 revenues of $8.4-$8.5 billion with mid-single-digit growth, down from 17% prior year growth. The company targets 50 basis points of operating margin expansion despite tariff headwinds, expecting tariffs to be neutral year-over-year. Coach brand remains strong at 86% of revenues with ~36% operating margins, while Kate Spade continues to post operating losses. TPR expects adjusted EPS of $7.80-$7.90, representing low-double-digit growth.
Tapestry Inc. (TPR) presents a mixed investment case with Coach brand driving strong 24% revenue growth and high-single-digit growth expected in fiscal 2027, while Kate Spade continues to struggle with a 10% revenue decline and $27.2 million operating loss. The company expects $7.80-$7.90 EPS in fiscal 2027 with $1.7 billion in capital returns, but trades at a premium valuation that leaves little room for execution errors.